Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy

被引：0
|
作者：
Megu Yamaguchi Baden
Akihisa Imagawa
Norio Abiru
Takuya Awata
Hiroshi Ikegami
Yasuko Uchigata
Yoichi Oikawa
Haruhiko Osawa
Hiroshi Kajio
Eiji Kawasaki
Yumiko Kawabata
Junji Kozawa
Akira Shimada
Kazuma Takahashi
Shoichiro Tanaka
Daisuke Chujo
Tomoyasu Fukui
Junnosuke Miura
Kazuki Yasuda
Hisafumi Yasuda
Tetsuro Kobayashi
Toshiaki Hanafusa
机构：
[1] Osaka University,Department of Metabolic Medicine, Graduate School of Medicine
[2] Osaka Medical College,Department of Internal Medicine (I)
[3] Nagasaki University Graduate School of Biomedical Sciences,Department of Endocrinology and Metabolism
[4] International University of Health and Welfare Hospital,Department of Diabetes, Endocrinology and Metabolism
[5] Kindai University Faculty of Medicine,Department of Endocrinology, Metabolism and Diabetes
[6] Tokyo Women’s Medical University Medical Center East,Department of Endocrinology and Diabetes, School of Medicine
[7] Saitama Medical University,Department of Laboratory Medicine
[8] Ehime University School of Medicine,Department of Diabetes, Endocrinology, and Metabolism
[9] Center Hospital of the National Center for Global Health and Medicine,Diabetes Center
[10] Shin-Koga Hospital,Faculty of Nursing and Graduate School of Nursing
[11] Iwate Prefectural University,Department of Internal Medicine, Division of Diabetes and Endocrinology
[12] Ai Home Clinic Toshima,Diabetes Center
[13] Showa University School of Medicine,Department of Metabolic Disorder, Diabetes Research Center, Research Institute
[14] Tokyo Women’s Medical University School of Medicine,Division of Health Sciences, Department of Community Health Sciences
[15] National Center for Global Health and Medicine,undefined
[16] Kobe University Graduate School of Health Sciences,undefined
[17] Okinaka Memorial Institute for Medical Research,undefined
[18] Sakai City Medical Center,undefined
来源：
Diabetology International | 2019年 / 10卷
关键词：
Nivolumab; Pembrolizumab; Anti-PD-1 antibody; Fulminant type 1 diabetes; Type 1 diabetes; Immune-checkpoint inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：58 / 66
页数：8
相关论文
共 50 条
  • [1] Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy
    Baden, Megu Yamaguchi
    Imagawa, Akihisa
    Abiru, Norio
    Awata, Takuya
    Ikegami, Hiroshi
    Uchigata, Yasuko
    Oikawa, Yoichi
    Osawa, Haruhiko
    Kajio, Hiroshi
    Kawasaki, Eiji
    Kawabata, Yumiko
    Kozawa, Junji
    Shimada, Akira
    Takahashi, Kazuma
    Tanaka, Shoichiro
    Chujo, Daisuke
    Fukui, Tomoyasu
    Miura, Junnosuke
    Yasuda, Kazuki
    Yasuda, Hisafumi
    Kobayashi, Tetsuro
    Hanafusa, Toshiaki
    Nagafuchi, Seiho
    Okamoto, Masahide
    Ogawa, Osamu
    Itateyama, Emi
    Ohtake, Hiroyuki
    Hirota, Yushi
    Tomoyasu, Masako
    Nakajima, Yasushi
    Yano, Seiichi
    Ashida, Kenji
    Kumagai, Ryo
    Yagyu, Hiroaki
    Koriyama, Nobuyuki
    Fukui, Michiaki
    Daikoku, Harumi
    Asai, Shiko
    Mochida, Akihiro
    Okajima, Fumitaka
    Takagi, Satoshi
    Nagasawa, Kaoru
    Taketomo, Yasunori
    [J]. DIABETOLOGY INTERNATIONAL, 2019, 10 (01) : 58 - 66
  • [2] Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
    Okamoto, Masahide
    Okamoto, Mitsuhiro
    Gotoh, Koro
    Masaki, Takayuki
    Ozeki, Yoshinori
    Ando, Hisae
    Anai, Manabu
    Sato, Asami
    Yoshida, Yuichi
    Ueda, So
    Kakuma, Tetsuya
    Shibata, Hirotaka
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (06) : 915 - 918
  • [3] Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy
    Ariyasu, Ryo
    Horiike, Atsushi
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Nishikawa, Shingo
    Kitazono, Satoru
    Yanagitani, Noriko
    Nishio, Makoto
    [J]. ANTICANCER RESEARCH, 2017, 37 (08) : 4229 - 4232
  • [4] Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
    Miyoshi, Yuka
    Ogawa, Osamu
    Oyama, Yu
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 239 (02): : 155 - 158
  • [5] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [6] Anti-programmed cell death-1 therapy in nonmelanoma skin cancer
    Winkler, J. K.
    Schneiderbauer, R.
    Bender, C.
    Sedlaczek, O.
    Froehling, S.
    Penzel, R.
    Enk, A.
    Hassel, J. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (02) : 498 - 502
  • [7] The path forward for anti-programmed cell death-1 therapy in gliomas
    Majd, Nazanin
    Kamiya-Matsuoka, Carlos
    de Groot, John
    [J]. CURRENT OPINION IN NEUROLOGY, 2019, 32 (06) : 864 - 871
  • [8] Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
    Martin-Liberal, Juan
    Furness, Andrew J. S.
    Joshi, Kroopa
    Peggs, Karl S.
    Quezada, Sergio A.
    Larkin, James
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 765 - 767
  • [9] Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
    Juan Martin-Liberal
    Andrew JS Furness
    Kroopa Joshi
    Karl S. Peggs
    Sergio A. Quezada
    James Larkin
    [J]. Cancer Immunology, Immunotherapy, 2015, 64 : 765 - 767
  • [10] Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report
    Kurihara, Susumu
    Oikawa, Yoichi
    Nakajima, Ritsuko
    Satomura, Atsushi
    Tanaka, Ryuhei
    Kagamu, Hiroshi
    Shimada, Akira
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (04) : 1006 - 1009
12345